Squarepoint’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Squarepoint’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,415	Closed	-$396K	–	4196
2023 Q1	$396K	Sell	16,415 -28,484	-63%	-$357K	﹤0.01%	2425
2022 Q4	$475K	Buy	+44,899	New	+$362K	﹤0.01%	2314
2021 Q3	–	Sell	-18,616	Closed	-$157K	–	3634
2021 Q2	$157K	Buy	+18,616	New	+$150K	﹤0.01%	2917
2021 Q1	–	Sell	-77,301	Closed	-$1.31M	–	3783
2020 Q4	$1.31M	Buy	+77,301	New	+$1.16M	0.01%	1167
2020 Q2	–	Sell	-19,282	Closed	-$177K	–	2605
2020 Q1	$177K	Buy	19,282 +4,120	+27%	+$53.1K	﹤0.01%	1516
2019 Q4	$226K	Buy	15,162 +1,252	+9%	+$11.2K	﹤0.01%	2176
2019 Q3	$95K	Buy	+13,910	New	+$141K	﹤0.01%	2199

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Squarepoint's PRVB Position: Q2 2023 in Review

Squarepoint sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 16,415 shares — an estimated $396K sold.

Squarepoint first reported a position in PRVB in Q3 2019 and held it in 7 quarters. The position peaked at $1.31M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Squarepoint reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Squarepoint sold 16,415 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $396K.
Squarepoint first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Squarepoint's Provention Bio, Inc. Common Stock position peaked at $1.31M in Q4 2020.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.